- Emyria (EMD) joins the Palantir’s Foundry Builders Program, giving it access to a sophisticated data platform
- The Palantir platform creates a central operating system for data and is owned by software company Palantir Technologies
- Emyria aims to use the platform for its proprietary Real World Evidence asset
- Emyria is up 4.88 per cent and is trading at 21.5 cents per share at 3:58 pm AEST
Emyria (EMD) has joined the Palantir’s Foundry Builders Program, giving it access to a sophisticated data platform.
The Palantir platform creates a central operating system for data.
The program is owned by software company Palantir Technologies and gives companies access to powerful and highly secure data integration and analysis software.
Under this program, Emyria will have access to the full Palantir Foundary stack, enhancing its data infrastructure, security, integration and analysis capabilities.
Emyria aims to use the platform for its proprietary Real World Evidence asset.
Managing Director Michael Winlo is pleased to be selected for the program.
“Real World Evidence is being increasingly used by major global drug regulators, like the FDA, to evaluate the safety and efficacy of new treatments,” Dr Winlo said.
“Palantir Foundry greatly improves our ability to secure, integrate, generate and analyse our Real World Evidence – both internally and with our global partners – meaning we can deliver on our mission to develop new treatments and improve patient care, faster.”
Emyria was up 4.88 per cent, trading at 21.5 cents per share at 3:58 pm AEST.